New York-based clinical-stage biotechnology company discovering and developing oncology therapeutics that target chromosomal instability (CIN), a vulnerability in cancer cells
New York-based clinical-stage biotechnology company discovering and developing oncology therapeutics that target chromosomal instability (CIN), a vulnerability in cancer cells. Its pipeline includes KIF18A inhibitors and uses synthetic lethality and immune activation approaches, supported by proprietary CIN-focused screening, computational modeling, and biomarker strategies.